GoAI
Get started
Crescent Biopharma, Inc. logo

Crescent Biopharma, Inc.

CBIO

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$17.15

+$0.92 · +5.67%

Aug 21, 4:00 PM ET

CBIO company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

58

Fair Value

Momentum

54

Neutral

Sentiment

55

Mixed

Risk resilience

36

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Joshua T. Brumm
Listed since
Jan 10, 2014
Employees
44

Market position

Day range

Current $17.15

52-week range

Current $17.15

Open
$16.39
Previous close
$16.23
Volume
218.39K
0.68× average
Average volume
321.28K
Average daily volume
Market cap
637.02M USD
Beta
1.22
Market reference 1
50-day average
$16.7148
+2.60% above average
200-day average
$15.1967
+12.85% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-2.26×
P/B (TTM)
3.21×
P/S (TTM)
53.61×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
100.00%
Operating margin
-1417.74%
Net margin
-1371.51%

Financial health

Debt / equity
0.01×
Altman Z-score
16.09
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends39385%-117756%-274897%-432038%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2021: -5470.69%Operating margin, FY2022: -63204.43%Operating margin, FY2023: -392752.93%Operating margin, FY2025: -1407.52%Net margin, FY2021: -5468.98%Net margin, FY2022: -62251.74%Net margin, FY2023: -368994.20%Net margin, FY2025: -1419.61%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2025 100.00%. Operating margin FY2021 -5470.69%. Operating margin FY2022 -63204.43%. Operating margin FY2023 -392752.93%. Operating margin FY2025 -1407.52%. Net margin FY2021 -5468.98%. Net margin FY2022 -62251.74%. Net margin FY2023 -368994.20%. Net margin FY2025 -1419.61%.

Income trends

Revenue

10.84M USD+108340.00%

Operating income

−152.63M USD-205.89%

Net income

−153.94M USD-217.25%
Income trends across reported periods27.32M USD−38.59M USD−104.51M USD−170.42M USDRevenue, FY2021: 1.16M USDRevenue, FY2022: 75K USDRevenue, FY2023: 10K USDRevenue, FY2025: 10.84M USDOperating income, FY2021: −63.45M USDOperating income, FY2022: −47.4M USDOperating income, FY2023: −39.28M USDOperating income, FY2024: −49.9M USDOperating income, FY2025: −152.63M USDNet income, FY2021: −63.43M USDNet income, FY2022: −46.69M USDNet income, FY2023: −36.9M USDNet income, FY2024: −48.52M USDNet income, FY2025: −153.94M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.16M USD. Revenue FY2022 75K USD. Revenue FY2023 10K USD. Revenue FY2025 10.84M USD. Operating income FY2021 −63.45M USD. Operating income FY2022 −47.4M USD. Operating income FY2023 −39.28M USD. Operating income FY2024 −49.9M USD. Operating income FY2025 −152.63M USD. Net income FY2021 −63.43M USD. Net income FY2022 −46.69M USD. Net income FY2023 −36.9M USD. Net income FY2024 −48.52M USD. Net income FY2025 −153.94M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue10.84M USD—10K USD75K USD1.16M USD
Gross profit10.84M USD—10K USD75K USD1.16M USD
Research and development138.09M USD28.06M USD20.07M USD28.39M USD47.49M USD
Selling, general, and administrative25.39M USD16.32M USD19.21M USD19.09M USD17.12M USD
Operating expenses163.48M USD49.9M USD39.29M USD47.48M USD64.61M USD
Interest income2.88M USD1M USD2.38M USD714.52K USD19.77K USD
Interest expense2.19M USD852K USD———
Depreciation and amortization84K USD35.17K USD153.3K USD207.15K USD264.6K USD
Operating income−152.63M USD−49.9M USD−39.28M USD−47.4M USD−63.45M USD
Net income−153.94M USD−48.52M USD−36.9M USD−46.69M USD−63.43M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-6.56%
11 comparable reports
Latest EPS result
-0.74
Estimate -0.74 · Miss by 0.58%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.03-1.82-3.61-5.4Q1 '25BeatQ2 '25BeatQ3 '25MissQ4 '25MissQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 13, 2025: actual -0.11, estimate -0.16, surprise +31.25%, Beat. Q2 2025, reported May 14, 2025: actual -0.04, estimate -5, surprise +99.20%, Beat. Q3 2025, reported Aug 6, 2025: actual -4.93, estimate -2.69, surprise -83.27%, Miss. Q4 2025, reported Nov 6, 2025: actual -1.27, estimate -1.01, surprise -25.74%, Miss. Q1 2026, reported Feb 26, 2026: actual -4.01, estimate -2.22, surprise -80.63%, Miss. Q2 2026, reported Apr 29, 2026: actual -0.7, estimate -0.85, surprise +17.65%, Beat. Q3 2026, reported Jul 30, 2026: actual -0.74, estimate -0.736, surprise -0.58%, Miss. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.662, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates33.01M22.01M11.01M8.5KQ1 '24No estimateQ4 '25EstimateQ1 '26BeatQ2 '26BeatQ3 '26EstimateQ4 '26Estimate
Q1 2024, reported Mar 27, 2024: actual 10K USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 6, 2025: actual —, estimate 30.56M USD, surprise —, Comparison unavailable. Q1 2026, reported Feb 26, 2026: actual 10.84M USD, estimate 10M USD, surprise +8.44%, Beat. Q2 2026, reported Apr 29, 2026: actual 1M USD, estimate 357.14K USD, surprise +180.00%, Beat. Q3 2026, reported Jul 30, 2026: actual —, estimate 357.14K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 357.14K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

2 institutions
TD CowendowngradeBuyHold

Corporate actions

Corporate action history

Stock split

Effective Jun 16, 2025

1:100

CBIO peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CBIO

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
13.12M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
8.64M
Weight
0.01%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
3.29M
Weight
0.02%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
1.76M
Weight
0.01%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.21M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
1.21M
Weight
0.08%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
Vanguard Health Care ETF logoVanguard Health Care ETFVHT
Market value
900.55K
Weight
0.00%
AUM
20.9B USD
Expense ratio
0.09%
Price / 1D
$327.7+1.24%
Vanguard Russell 2000 Growth ETF logoVanguard Russell 2000 Growth ETFVTWG
Market value
337.7K
Weight
0.02%
AUM
1.7B USD
Expense ratio
0.06%
Price / 1D
$282.73+1.21%

Continue in GoAI

Research CBIO

research.disclaimer